FindTrial
Sign In

CC-4047

DRUG6 trials

Sponsors

Celgene Corporation, Case Comprehensive Cancer Center, Mayo Clinic, Washington University School of Medicine, M.D. Anderson Cancer Center

Conditions

Chronic Myeloproliferative DisordersGraft vs Host DiseaseMultiple MyelomaPolycythemia VeraProstate CancerSecondary MyelofibrosisThrombocythemiaUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

CC-4047 in Treating Patients With Advanced Solid Tumors That Did Not Respond to Treatment
CompletedNCT00482521
Case Comprehensive Cancer CenterUnspecified Adult Solid Tumor, Protocol Specific
Start: 2007-03-31End: 2012-08-31Updated: 2012-08-28
CC-4047 in Treating Patients With Myelofibrosis
CompletedNCT00669578
Mayo ClinicChronic Myeloproliferative Disorders, Secondary Myelofibrosis
Start: 2008-05-31End: 2019-12-12Updated: 2019-12-30

Phase 2

Safety and Efficacy of CC-4047 in Subjects With Metastatic Hormone Refractory Prostate Cancer (HRPC)
CompletedNCT00072722
Celgene CorporationProstate Cancer
Start: 2003-09-30End: 2005-04-30Target: 36Updated: 2006-12-19
CC-4047 (Pomalidomide) for Graft vs. Host Disease
CompletedNCT00770757
Washington University School of MedicineGraft vs Host Disease
Start: 2009-02-28End: 2011-10-31Updated: 2016-02-25
Pomalidomide for Myelofibrosis Patients
CompletedNCT00946270
M.D. Anderson Cancer CenterPolycythemia Vera, Thrombocythemia
Start: 2009-07-22End: 2018-05-22Updated: 2019-06-10

Unknown Phase

Expanded Access for CC-4047
NCT03723096
CelgeneMultiple Myeloma
Updated: 2018-12-20

Related Papers

Efficacy and Safety of Pomalidomide in Combination with Prednisone in Patients with Myelofibrosis and Anemia — Final Results of a Prospective Phase 2 Study
Blood2018-11-291 citations
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
2014-07-0627 citations
Decrease Of T Regulatory Cells In Patients With Myelofibrosis Receiving Ruxolitinib
Blood2013-11-157 citations